Professor, Pathology and Laboratory Medicine, Perelman School of Medicine
Pathology
Dr. John Q. Trojanowski, MD
|
|
Give Review
John Q. Trojanowski is an expert in the field of Pathology. He went to Tufts University School of Medicine. Tufts University School of Medicine has a rank of 49 in research and a 52 in primary care He over the years received 3 awards: "Elected Member", "Whos Who in Medicine and Healthcare" and "Super Doctor". John Trojanowski is a published doctor. He published 100 publications, including: 'The Penn Parkinson's Daily Activities Questionnaire-15: Psychometric properties of a brief assessment of cognitive instrumental activities of daily living in Parkinson...'
Publications
- Pathological α-synuclein distribution in subjects with coincident Alzheimer's and Lewy body pathology.
- The Penn Parkinson's Daily Activities Questionnaire-15: Psychometric properties of a brief assessment of cognitive instrumental activities of daily living in Parkinson...
- Multisite assessment of NIA-AA guidelines for the neuropathologic evaluation of Alzheimer's disease.
- Deep Clinical and Neuropathological Phenotyping of Pick's Disease.
- Functional recovery in new mouse models of ALS/FTLD after clearance of pathological cytoplasmic TDP-43.
- Semi-Automated Digital Image Analysis of Pick's Disease and TDP-43 Proteinopathy.
- Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression.
- Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease.
- Correlating Cognitive Decline with White Matter Lesion and Brain Atrophy Magnetic Resonance Imaging Measurements in Alzheimer's Disease.
- Drosha Inclusions Are New Components of Dipeptide-Repeat Protein Aggregates in FTLD-TDP and ALS C9orf72 Expansion Cases.
- Frontotemporal lobar degeneration: defining phenotypic diversity through personalized medicine.
- The TMEM106B locus and TDP-43 pathology in older persons without FTLD.
- Nonlinear Association Between Cerebrospinal Fluid and Florbetapir F-18 β-Amyloid Measures Across the Spectrum of Alzheimer Disease.
- Pharmacokinetic, pharmacodynamic and metabolic characterization of a brain retentive microtubule (MT)-stabilizing triazolopyrimidine.
- Building a roadmap for developing combination therapies for Alzheimer's disease.
- Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways.
- Cognitive profile of LRRK2-related Parkinson's disease.
- CSF beta-amyloid 1-42 - what are we measuring in Alzheimer's disease?
- Spreading of pathology in neurodegenerative diseases: a focus on human studies.
- Brain amyloidosis ascertainment from cognitive, imaging, and peripheral blood protein measures.
- The transitional association between β-amyloid pathology and regional brain atrophy.
- Differential induction and spread of tau pathology in young PS19 tau transgenic mice following intracerebral injections of pathological tau from Alzheimer's disease or...
- Rarity of the Alzheimer Disease-Protective APP A673T Variant in the United States.
- Primary age-related tauopathy (PART): a common pathology associated with human aging.
- Role of cerebrospinal fluid biomarkers in clinical trials for Alzheimer's disease modifying therapies.
- Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease.
- Clinical Correlations With Lewy Body Pathology in LRRK2-Related Parkinson Disease.
- Abnormal serine phosphorylation of insulin receptor substrate 1 is associated with tau pathology in Alzheimer's disease and tauopathies.
- Effects of Multiple Genetic Loci on Age at Onset in Late-Onset Alzheimer Disease: A Genome-Wide Association Study.
- FASTKD2 is associated with memory and hippocampal structure in older adults.
- Genome-Wide Association Meta-analysis of Neuropathologic Features of Alzheimer's Disease and Related Dementias.
- Potent, long-acting cyclopentane-1,3-Dione thromboxane (A2)-receptor antagonists.
- APOE, MAPT, and SNCA Genes and Cognitive Performance in Parkinson Disease.
- Evaluation of the cyclopentane-1,2-dione as a potential bio-isostere of the carboxylic acid functional group.
- Intracerebral injection of preformed synthetic tau fibrils initiates widespread tauopathy and neuronal loss in the brains of tau transgenic mice.
- Lower plasma Apolipoprotein A1 levels are found in Parkinson's disease and associate with apolipoprotein A1 genotype.
- Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research.
- Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease.
- Variables associated with hippocampal atrophy rate in normal aging and mild cognitive impairment.
- History of cigarette smoking in cognitively-normal elders is associated with elevated cerebrospinal fluid biomarkers of oxidative stress.
- Brain-Penetrant, Orally Bioavailable Microtubule-Stabilizing Small Molecules Are Potential Candidate Therapeutics for Alzheimer's Disease and Related Tauopathies.
- At the interface of sensory and motor dysfunctions and Alzheimer's disease.
- Perforant path synaptic loss correlates with cognitive impairment and Alzheimer's disease in the oldest-old.
- Frontotemporal dementia and its subtypes: a genome-wide association study.
- A platform for discovery: The University of Pennsylvania Integrated Neurodegenerative Disease Biobank.
- A comparison of Aβ amyloid pathology staging systems and correlation with clinical diagnosis.
- TDP-43 pathology and neuronal loss in amyotrophic lateral sclerosis spinal cord.
- α-Synuclein Immunotherapy Blocks Uptake and Templated Propagation of Misfolded α-Synuclein and Neurodegeneration.
- Effects of traumatic brain injury and posttraumatic stress disorder on Alzheimer's disease in veterans, using the Alzheimer's Disease Neuroimaging Initiative.
- Astrocytic TDP-43 Pathology in Alexander Disease.
- Emerging β-Amyloid Pathology and Accelerated Cortical Atrophy.
- Qualification of a Surrogate Matrix-Based Absolute Quantification Method for Amyloid-β42 in Human Cerebrospinal Fluid Using 2D UPLC-Tandem Mass Spectrometry.
- TMEM106B is a genetic modifier of frontotemporal lobar degeneration with C9orf72 hexanucleotide repeat expansions.
- Sequential distribution of pTDP-43 pathology in behavioral variant frontotemporal dementia (bvFTD).
- The power of neuroimaging biomarkers for screening frontotemporal dementia.
- Phosphorylated Tau as a Candidate Biomarker for Amyotrophic Lateral Sclerosis.
- The Growth and Impact of Alzheimer Disease Centers as Measured by Social Network Analysis.
- Absence of C9ORF72 expanded or intermediate repeats in autopsy-confirmed Parkinson's disease.
- Aminothienopyridazines as imaging probes of tau pathology: a patent evaluation of WO2013090497.
- CSF Apo-E levels associate with cognitive decline and MRI changes.
- Analysis of CSF mitochondrial DNA levels in Alzheimer disease.
- The future of blood-based biomarkers for Alzheimer's disease.
- In vivo signatures of nonfluent/agrammatic primary progressive aphasia caused by FTLD pathology.
- Practical utility of amyloid and FDG-PET in an academic dementia center.
- Low Plasma Leptin inMild Cognitively Impaired/Alzheimer's disease ADNI1 subjects- gender differences and diagnostic and therapeutic potential.
- Therapeutic modulation of eIF2α phosphorylation rescues TDP-43 toxicity in amyotrophic lateral sclerosis disease models.
- Microtubule-stabilizing agents as potential therapeutics for neurodegenerative disease.
- Genetic and neuroanatomic associations in sporadic frontotemporal lobar degeneration.
- Alzheimer's disease biomarkers: walk with deliberate haste, don't run blithely on?
- Effects of cerebrospinal fluid proteins on brain atrophy rates in cognitively healthy older adults.
- Association of plasma C-reactive protein levels with the diagnosis of Alzheimer's disease.
- Neuropsychologic assessment in collaborative Parkinson's disease research: A proposal from the National Institute of Neurological Disorders and Stroke Morris K. Udall ...
- Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies.
- MT-Stabilizer, Dictyostatin, Exhibits Prolonged Brain Retention and Activity: Potential Therapeutic Implications.
- TDP-43 Pathology, Cognitive Decline, and Dementia in Old Age.
- The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception.
- Acetylated tau neuropathology in sporadic and hereditary tauopathies.
- Distinct α-Synuclein Strains Differentially Promote Tau Inclusions in Neurons.
- Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer's Coordinating Centre.
- Many roads to Parkinson's disease neurodegeneration: Head trauma-A road more traveled than we know?
- A comparative survey of the topographical distribution of signature molecular lesions in major neurodegenerative diseases.
- Clinical and Biochemical Differences in Patients Having Parkinson Disease With vs Without GBA Mutations.
- CSF α-synuclein improves diagnostic and prognostic performance of CSF tau and Aβ in Alzheimer's disease.
- Longitudinal change in CSF Tau and Aβ biomarkers for up to 48 months in ADNI.
- Deciphering amyotrophic lateral sclerosis: What phenotype, neuropathology and genetics are telling us about pathogenesis.
- Stages of pTDP-43 pathology in amyotrophic lateral sclerosis.
- CSF biomarker variability in the Alzheimer's Association quality control program.
- Topography of FUS pathology distinguishes late-onset BIBD from aFTLD-U.
- GWAS of Cerebrospinal Fluid Tau Levels Identifies Risk Variants for Alzheimer's Disease.
- Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS.
- Plasma amyloid beta measurements - a desired but elusive Alzheimer's disease biomarker.
- Neocortical ?-amyloid area is associated with dementia and APOE in the oldest-old.
- Clinical Utility and Analytical Challenges in Measurement of Cerebrospinal Fluid Amyloid-?1-42 and ? Proteins as Alzheimer Disease Biomarkers.
- Association of plasma and cortical amyloid beta is modulated by APOE ?4 status.
- White matter imaging helps dissociate tau from TDP-43 in frontotemporal lobar degeneration.
- Cerebrospinal fluid biomarkers for differentiation of frontotemporal lobar degeneration from Alzheimer's disease.
- Relationship between Plasma Analytes and SPARE-AD Defined Brain Atrophy Patterns in ADNI.
- Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers.
- Plasma apolipoprotein A1 as a biomarker for parkinson's disease.
Schools
Tufts University
Massachusetts General Hospital
Hospital Of The University Of Pennsylvania
PHD Tufts
Doctors Specialties
- Neuropathology
- Pathology
Accepted Insurances
Awards
- Elected Member
- Whos Who in Medicine and Healthcare
- Super Doctor
Education
-
University of Pennsylvania Health System -
Massachusetts General Hospital -
Tufts University School of Medicine
Hospital
-
Hospital of the University of Pennsylvania -
Pennsylvania Hospital -
Penn Presbyterian Medical Center
Helpful Reviews
Similar Doctors
|
|
Dr. Sherri S. Besmer, MD |
|
|
Dr. Christian J. Davidson, MD |
|
|
Dr. Christos D. Katsetos, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Pallavi P. Gopal, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lyndsey A. Emery, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ronnie M. Abraham, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Harry S. Cooper, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Abir L. Mukherjee, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Douglas O. Reale, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mark T. Curtis, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Bruce H. Wainer, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sriram Venneti, MD |
|
|
Dr. Kimberly L. Dumoff, MD
This Doctor is OpenDoctor Recommended.
|